Introduction

Mechanisms of CMS
The pathophysiological sequence of CMS can be understand as follows, a decrease of the ventilatory function at high altitude produces hypoxemia, which is at the basis of the excessive erythrocytosis. . Based on the above physiologic observations and epidemiological studies, we proposed that at high altitude, as age increases, CMS will increase its prevalence. .
CMS in women
Some years ago, CMS was considered an almost exclusively male condition, since little was known about its prevalence and associated risk factors in women. Pre-menstrual women have been thought to be protected from CMS because the female hormones, progestin and estrogen, increase alveolar ventilation
CMS and age
With normal aging, arterial oxygen pressure (PaO2) decreases linearly, from about 95 Torr at the age of 20 to about 75 Torr at the age of 75. (10) The hemoglobin-oxygen equilibrium curve is sigmoid in shape, and varies little with altitude.(12) Thus at sea level, SaO2 of 85% or more falls on a flat part of the OEC, so that small changes in PaO2 have little effect on saturation. However, at altitude, where PaO2 is lower, small changes in PO2 can have large effects on saturation and the same changes that accompany aging may have significant effects on arterial hemoglobin saturation and therefore arterial oxygen content (CaO2).
Monge C. and Whittembury have shown, by combining the equation describing the PaO 2 drop with age with the one describing the hemoglobin response to PaO 2 in high altitude natives, that the increase in hematocrit at high altitude as a function of age can be predicted.(11) Based on the above physiologic observations and epidemiological studies, we proposed that at high altitude, as age increases, CMS will increase its prevalence. Figure 1 shows indirectly that age is an important contributory factor for the development of excessive erythrocytosis and CMS. It indicates that ventilation of Andean high altitude natives responds poorly to acute hypoxia and hyperoxia, but does respond to CO 2 added to the inspired air. However, all these responses fall with age and, therefore, an appropriate response to CO 2 does not mean that the ventilation will be independent of age. Arai et al. (12) have shown that PaCO 2 increases with age at altitudes between 3,450 to 3,850 m., in other words ventilation decreases with age. Additionally, vital capacity of high altitude men decreases more with age than that of sea level men, together with a decrease in oxygen saturation. Observational studies have not shown a correlation between CMS and age, but they have been based in small sample of cases. The comparison of prevalences of people with CMS at different ages should be more likely to reveal the effect of aging on the prevalence of CMS in a certain population.
In addition to the role played by the age-related decrease in ventilation in the etiology of CMS,(13) other additional factors may be involved in the development of CMS: an increase in the alveolar-arterial O 2 gradient with possible venous-arterial shunting and a reduction of the ventilation-perfusion ratio,(14,15) .
-- Arterial PCO 2 showed a sharp rise after age 40, reaching values similar to or above those of men.
These observations support the notion that ventilatory drive in women has an important hormonal component, and that this stimulus decreases after menopause. --
CMS and metals
Prevention and treatment of CMS
In recent times, increasing attention is being paid to different aspects that may be involved in the causal chain of CMS and were previously overlooked, Acetazolamide has been studied in randomized, placebo-controlled trials in the Peruvian Andes20~23）. Although the first study included a relatively small number of subjects and 3 weeks follow-up, the second one followed patients for up to 6 months. Improvement of excessive erythrocytosis and ventilatory response were encouraging in these studies.
Due to the chronic relapsing nature of CMS, it is clear that both enalapril and acetazolamide need further large non-inferiority clinical trials that assess their comparative efficacy on several years of follow-up.
-- There is great variability in susceptibility, so one of the challenges is to explain not only the causes for its signs and symptoms, but also why at any given altitude some individuals are more likely to develop CMS than others. In addition to the physiological variables that lead to the pathophysiological sequence of CMS, other etiologic factors, of genetic origin, must also be considered. Studies at the molecular level should follow, looking for the genetic and molecular basis of the disease, i.e., the variability in HVR and EPO response, hemoglobin levels, etc. Furthermore, studies
Conclusions and the way forward
should be undertaken at the microvascular level to understand the patterns of O2 distribution in vessels of various sizes and the distribution of hematocrit and viscosity in these vessels.
In general there is a need to learn more about living, getting sick and getting older in the high altitude areas and CMS has provided the opportunity to expand our knowledge about the mechanisms found at different levels of acclimatization to high altitude. We have to continue research on this area as well as looking for better preventing and therapeutic alternatives.
